Investors with the goal of beating the broader market often turn to stock selection. Strategic choices in individual stocks can have a profound impact on your wealth.
In the latest session, Esperion Therapeutics Inc (NASDAQ: ESPR) closed at $3.65 down -1.62% from its previous closing price of $3.71. In other words, the price has decreased by -$1.62 from its previous closing price. On the day, 3.02 million shares were traded. ESPR stock price reached its highest trading level at $3.75 during the session, while it also had its lowest trading level at $3.63.
Ratios:
For a deeper understanding of Esperion Therapeutics Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.76 and its Current Ratio is at 1.15.
Upgrades & Downgrades
In the most recent recommendation for this company, Piper Sandler on November 25, 2025, initiated with a Overweight rating and assigned the stock a target price of $9.
On December 18, 2024, Goldman started tracking the stock assigning a Neutral rating and target price of $4.
On December 17, 2024, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $8.Cantor Fitzgerald initiated its Overweight rating on December 17, 2024, with a $8 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Dec 17 ’25 when Koenig Sheldon L. bought 48,244 shares for $3.67 per share.
Looker Benjamin bought 6,517 shares of ESPR for $23,897 on Dec 17 ’25. On Dec 17 ’25, another insider, Halladay Benjamin, who serves as the Officer of the company, bought 7,337 shares for $3.67 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ESPR now has a Market Capitalization of 865302720 and an Enterprise Value of 1373840768. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.87. Its current Enterprise Value per Revenue stands at 4.522 whereas that against EBITDA is -46.93.
Stock Price History:
The Beta on a monthly basis for ESPR is 1.05, which has changed by 0.70967746 over the last 52 weeks, in comparison to a change of 0.15905356 over the same period for the S&P500. Over the past 52 weeks, ESPR has reached a high of $4.13, while it has fallen to a 52-week low of $0.69. The 50-Day Moving Average of the stock is 16.56%, while the 200-Day Moving Average is calculated to be 88.14%.
Shares Statistics:
For the past three months, ESPR has traded an average of 7.01M shares per day and 5189210 over the past ten days. A total of 239.06M shares are outstanding, with a floating share count of 235.34M. Insiders hold about 1.56% of the company’s shares, while institutions hold 52.99% stake in the company. Shares short for ESPR as of 1764288000 were 28728824 with a Short Ratio of 4.10, compared to 1761868800 on 25922850. Therefore, it implies a Short% of Shares Outstanding of 28728824 and a Short% of Float of 12.16.
Earnings Estimates
A detailed examination of Esperion Therapeutics Inc (ESPR) is currently in progress, with 7.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is -$0.01, with high estimates of $0.07 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.23 and -$0.42 for the fiscal current year, implying an average EPS of -$0.07. EPS for the following year is $0.03, with 7.0 analysts recommending between $0.4 and -$0.32.
Revenue Estimates
A total of 8 analysts believe the company’s revenue will be $164.7M this quarter.It ranges from a high estimate of $211.4M to a low estimate of $97.33M. As of. The current estimate, Esperion Therapeutics Inc’s year-ago sales were $69.11MFor the next quarter, 8 analysts are estimating revenue of $109.49M. There is a high estimate of $155.84M for the next quarter, whereas the lowest estimate is $88.1M.
A total of 8 analysts have provided revenue estimates for ESPR’s current fiscal year. The highest revenue estimate was $446.1M, while the lowest revenue estimate was $283.93M, resulting in an average revenue estimate of $393.11M. In the same quarter a year ago, actual revenue was $332.31MBased on 8 analysts’ estimates, the company’s revenue will be $379.59M in the next fiscal year. The high estimate is $433.01M and the low estimate is $339.03M.
